Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials
Hung‐Yang Kuo, Kabir A. Khan, Robert S. Kerbel
Topics & Concepts
MedicineClinical trialImmune systemBlockadeVascular endothelial growth factorAfliberceptCancer researchAngiogenesisPharmacologyBevacizumabOncologyImmunologyVEGF receptorsInternal medicineChemotherapyReceptorCancer Genomics and DiagnosticsRenal cell carcinoma treatmentAngiogenesis and VEGF in Cancer